Company intelligence / Profile preview

Algomedix

Mill Creek, Washington, United Statesalgomedix.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Algomedix is developing novel TRP channel therapeutics using a rational drug design approach. Their lead programs include a TRPA1 antagonist for pain and a TRPC6 antagonist for chronic kidney disease, both in preclinical development.

Therapeutic areas: PulmonologyNephrologyOphthalmologyEndocrinologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ALGX-XC20

Pre-clinical

Indications: Osteoarthritis pain

Beyond the preview

Go deeper on Algomedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Algomedix.

Explore the full profile